Story perspectives

Novo Nordisk Launches Oral Wegovy, Competes with Eli Lilly

4/16/2026

Summary

Story summary

Novo Nordisk leads the cardiometabolic market with its semaglutide-based drugs, Ozempic and Wegovy.
In early 2026, Novo Nordisk launched an oral version of Wegovy after receiving FDA approval.
Eli Lilly's drugs, Mounjaro and Zepbound, have gained market share due to their effectiveness and strategies.
Lilly recently introduced its oral GLP-1 therapy, Foundayo, which competes with Wegovy.
Novo Nordisk claims its oral Wegovy has better clinical outcomes than Foundayo, based on indirect comparisons.

1 of 1

Story summary

Novo Nordisk leads the cardiometabolic market with its semaglutide-based drugs, Ozempic and Wegovy.
In early 2026, Novo Nordisk launched an oral version of Wegovy after receiving FDA approval.
Eli Lilly's drugs, Mounjaro and Zepbound, have gained market share due to their effectiveness and strategies.
Lilly recently introduced its oral GLP-1 therapy, Foundayo, which competes with Wegovy.
Novo Nordisk claims its oral Wegovy has better clinical outcomes than Foundayo, based on indirect comparisons.